Compare Automatic Data Processing Inc (ADP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $107.69B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Automatic Data Processing Inc pays a 2.51% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Automatic Data Processing Inc nearer its low. Which is the better fit depends on your goals.
| ADP | XBI | |
|---|---|---|
Market Cap | $107.69B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $309.03 | $164.28 |
52-Week Low | $188.79 | $86.92 |
Enterprise Value | $108.73B | — |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $269.14, down 1.66% on the day, with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings, beating estimates with EPS of $2.62 versus $2.57 expected, and revenue growth continues steadily. Analyst consensus is a $280.50 price target, though the majority rating is Hold. Recent news highlights dividend declarations and employment data reports.
Outlook remains positive due to consistent earnings beats and margin expansion, but high valuation multiples like a P/E of 24.78 pose a risk if growth slows. Key risks include economic sensitivity affecting payroll services demand and competitive pressures in HR solutions.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
